Mesothelioma Clinical Trial Combines Immunotherapy Drugs – Asbestos.com
Asbestos.com |
Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Asbestos.com Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope … |
